The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database

PURPOSE: Compare the risk of melanoma between initiators of rasagiline or other antiparkinsonian drugs (APDs) in a Parkinson's disease (PD) population. METHODS: A retrospective cohort study was conducted in the US Medicare claims research database (2006–2015) in adults aged ≥65 years with PD cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Johannes, Catherine B., Saltus, Catherine W., Kaye, James A., Calingaert, Brian, Kaplan, Sigal, Gordon, Mark Forrest, Andrews, Elizabeth B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321028/
https://www.ncbi.nlm.nih.gov/pubmed/35224798
http://dx.doi.org/10.1002/pds.5422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321028/
https://www.ncbi.nlm.nih.gov/pubmed/35224798
http://dx.doi.org/10.1002/pds.5422

Ejemplares similares